X4 Pharmaceuticals secures $150m debt facility with K2 HealthVentures
X4 Pharmaceuticals has entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures, replacing its prior lending arrangement and giving the NASDAQ-listed biotech a longer runway as it advances its lead candidate, mavorixafor, through a pivotal Phase 3 trial in chronic neutropenia.
The first tranche of $80 million was drawn at closing and used to repay the previous facility in full, including $75 million of principal and associated fees. A further $70 million remains available at X4's request, subject to K2 HealthVentures' approval and unspecified conditions. The new structure carries a 48-month maturity and an extended interest-only period, providing greater near-term financial flexibility than the arrangement it replaces.
The deal
David Kirske, chief financial officer at X4, said the refinancing puts the company on "a solid financial foundation" as it works towards a potential FDA approval and commercial launch of mavorixafor in chronic neutropenia. He added that X4 expects to complete enrolment in the Phase 3 4WARD trial before the end of 2026, with topline data anticipated in the first half of 2028.
Parag Shah, founding managing director and chief executive of K2 HealthVentures, described the transaction as consistent with the firm's strategy of providing long-term financing to innovative life sciences companies. K2 HealthVentures is an alternative investment firm that focuses on flexible debt solutions for the healthcare sector, and has backed a range of clinical-stage and commercial-stage companies.
Mavorixafor is already approved in the United States and European Union under the brand name XOLREMDI for WHIM syndrome, a rare primary immunodeficiency caused by a CXCR4 mutation. The 4WARD trial represents X4's attempt to extend the drug's label into chronic neutropenic disorders more broadly, a category that encompasses several conditions characterised by persistently low neutrophil counts and recurring serious infections. The FDA has granted Fast Track designation to mavorixafor for this second indication.
Market context and regulatory path
Debt financing of this structure, sometimes called venture debt or royalty-linked lending, has become an increasingly common capital tool for clinical-stage biotechs seeking to avoid equity dilution while extending runway through late-stage development. K2 HealthVentures operates in a competitive field alongside firms such as Hercules Capital, Horizon Technology Finance and Silicon Valley Bank's life sciences division, each of which has grown its healthcare lending book over the past several years.
For X4 specifically, the refinancing is strategically significant because the interest-only extension is tied, in part, to achieving first commercial sales of mavorixafor in chronic neutropenia on a defined schedule. If those sales are delayed, the terms of the facility could tighten, a risk the company acknowledges explicitly in its forward-looking statements. Investors will therefore watch the 4WARD enrolment completion and the subsequent 2028 topline readout as dual catalysts that bear directly on both regulatory and financing outcomes.
With XOLREMDI already generating revenue in WHIM syndrome, X4 has a commercial infrastructure to build from. However, chronic neutropenia is a broader and more heterogeneous patient population, and the 4WARD trial will need to demonstrate a sufficiently robust clinical benefit to justify label expansion in a competitive rare-haematology landscape where treatment options, though limited, are increasingly under scrutiny from payers seeking evidence of cost-effectiveness.